Frost & Sullivan Honours CytoNiche with 2025 “Global Intelligent Cell Manufacturing Technology Innovation Leadership Award”

Date : 2025-08-28

Publisher : Cytoniche | Marketing

SHANGHAI & SINGAPORE — August 28, 2025 — CytoNiche is honoured to receive Frost & Sullivan’s 2025 Global Intelligent Cell Manufacturing Technology Innovation Leadership Award at the Growth, Innovation & Leadership (GIL) Awards Ceremony in Shanghai.

The award was presented to Dr. Yan Xiaojun, Co-founder & CTO of CytoNiche.

Frost & Sullivan’s GIL Awards recognise companies across regional and global markets for leadership and innovation. Now in its third decade, the program is widely regarded for the rigour and impartiality of its methodology.

Following sustained research on the global cell manufacturing sector and comparative assessments of leading companies, Frost & Sullivan recognised CytoNiche for its large-scale 3D intelligent cell manufacturing technology and successful commercialisation cases. The company’s core technology—3D TableTrix™ & 3D RecomTrix™ dissolvable, porous microcarriers—underpins CytoNiche’s 3D Cell Intelligent Manufacturing Platform and an end-to-end workflow spanning cell expansion, culture, harvest, processing, and fill & finish. The platform enables large-scale, closed, and automated production of cells and cell-derived products, achieving single-batch yields in the hundreds of billions of cells.

Built on this production pipeline, CytoNiche has supported multiple global stem-cell drug developers in establishing state-of-the-art manufacturing pipelines, helping slash the cost of goods through reduced consumables, labour, and cycle time while accelerating clinical and commercial timelines. To date, the company has supported several new stem-cell therapies through clinical trial application approvals and contributed to the approval of China’s first stem-cell therapy.

In July, CytoNiche established its international headquarters and 3D FloTrix Experience Hub in Singapore, advancing the company’s strategy of “technology for shared industry growth.” Leveraging Singapore’s strategic status, CytoNiche aims to broaden access to its technologies and support the global development of the cell and gene therapy (CGT) field.

Receiving this honour reflects recognition from across the industry and carries higher expectations for what comes next. Cytoniche will continue to drive technological innovation, deepen technical exchange, and expand international collaboration—bringing Asian innovation and efficient manufacturing to more partners worldwide, ultimately benefiting more patients.

The Senior Vice President of Danaher and Delegation Visited CytoNiche to Discuss New Future of Cell Therapy and Scalable Production

Closing the CMC Gap: How Next-Gen Manufacturing Unlocks the True Promise of MSCs